Pfizer Inc. (PFE)


NYSE - NYSE Real Time Price. Currency in USD
35.25+0.16 (+0.46%)
As of 10:47 AM EDT. Market open.
People also watch:
MRKJNJJPMGEINTC
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open35.23
Prev Close35.09
Bid35.35 x 5600
Ask35.36 x 2800
Day's Range35.09 - 35.38
52wk Range28.25 - 37.39
1y Target EstN/A
Market Cap213.81B
P/E Ratio (ttm)31.25
Beta0.96
Volume4,317,257
Avg Vol (3m)22,247,406
Dividend & Yield1.20 (3.44%)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Tesla takes fast to new level, Pfizer inks another deal, Fitbit pops after trade secrets win
    Editor's Pick
    Yahoo Finance57 minutes ago

    Tesla takes fast to new level, Pfizer inks another deal, Fitbit pops after trade secrets win

    Pfizer (PFE) shares remain in the spotlight. The US drug maker that bought cancer drug firm Medivation (MDVN) just a couple of days ago is now buying part of AstraZeneca’s (AZN) antibiotics business. FitBit (FIT) shares got a healthy pop ahead of the open after a US trade judge ruled late Tuesday that the maker of wearable fitness trackers did not steal trade secrets from rival Jawbone.

  • Pfizer buys Medivation for $14B; Citi's bullish call on Foot Locker; Valeant management shakeup
    Editor's Pick
    Seana Smith2 days ago

    Pfizer buys Medivation for $14B; Citi's bullish call on Foot Locker; Valeant management shakeup

    Pfizer is buying Medivation for $14 billion. Medivation’s portfolio includes Xtandi, a treatment for prostate cancer that generates about $2 billion in worldwide annual sales. Valeant Pharmaceuticals (VRX) — Zoetis (ZTS) Chief Financial Officer Paul Herendeen has stepped down to become executive vice president of finance at Valeant and will take over the role of CFO from Robert Rosiello effective immediately.

  • The $14 billion Pfizer drug deal is a nice win for a bunch of hedge funds
    Editor's Pick
    Julia La Roche2 days ago

    The $14 billion Pfizer drug deal is a nice win for a bunch of hedge funds

    On Monday, Medivation’s (MDVN) stock surged around 20% after pharma giant Pfizer (PFE) said it would acquire the biotech company in a $14 billion deal. Medivation just made its debut on Goldman Sachs’ 50 stocks that “matter most” to hedge funds list, ranking No. 17 on the list. Some hedge funds that opened a new position in Medivation during the second quarter include York Capital Management (5.07 million shares), Tourbillon Capital Partners (4.72 million shares), Pentwater Capital (4.28 million shares), and Eton Park Capital Management (3.08 million shares), 13-F filings show.